Kisspeptin-10: The Peptide That Started Puberty in Mice With No Receptor

The Receptor Came First

The unusual thing about kisspeptin is that it was identified backwards. Most peptide hormone stories begin with someone noticing a biological effect and tracing it to a molecule. Kisspeptin's story begins with a receptor that nobody knew was important, attached to a phenotype that looked like nothing else.

GPR54 was an orphan G-protein-coupled receptor first cloned in the late 1990s. Nobody knew its endogenous ligand or what it did. Then two papers in 2003, one in The New England Journal of Medicine and one in PNAS, independently identified loss-of-function mutations in the GPR54 gene as a cause of isolated hypogonadotropic hypogonadism — a condition where puberty fails to start because the hypothalamus stops sending the right signals to the pituitary.

Seminara and her colleagues at Massachusetts General Hospital traced the mutation through a consanguineous Saudi family. De Roux's group in Paris found the same gene in a different cohort, by a different route. Both papers hit the literature within months. And the same year, two pharmaceutical groups working on orphan GPCR deorphanization — Funes at Pfizer and Kotani at Takeda — both identified kisspeptin as the endogenous ligand of GPR54. Four convergent papers in twelve months. The field was rebuilt around them.

What Kisspeptin Actually Is

The KISS1 gene was originally characterized in the mid-1990s in the context of melanoma metastasis suppression — which is, somewhat famously, where the name comes from (KISS for "kiss" was a Hershey, Pennsylvania reference; the original cloners called it the metastasis suppressor). The gene encodes a 145-amino-acid precursor that is processed in vivo to a 54-residue active peptide, kisspeptin-54. KP-54 is then further cleaved to KP-14, KP-13, and KP-10.

All four cleavage products bind GPR54. The C-terminal Arg-Phe-NH₂ sequence is the receptor-binding motif, and any kisspeptin fragment retaining it remains active. KP-10 is the smallest active form. It's what most research uses, because synthesizing a 10-residue peptide is straightforward, and at equipotent doses KP-10 produces the same acute effects as KP-54 on gonadotropin secretion.

Where the Neurons Are

Kisspeptin neurons in the brain are concentrated in two hypothalamic regions. The arcuate nucleus contains a large population that co-expresses kisspeptin, neurokinin B, and dynorphin (the so-called KNDy neurons, because of the three peptides). The anteroventral periventricular nucleus contains a sexually dimorphic kisspeptin population that's larger in females than males and is involved in the LH surge that triggers ovulation.

The KNDy population in the arcuate is now widely believed to be the GnRH pulse generator. This was a long-standing mystery in reproductive neuroendocrinology — researchers knew GnRH was secreted in pulses every 60-90 minutes, but the upstream rhythm-generating circuit hadn't been pinned down. Tract tracing showed KNDy neurons project directly to GnRH cell bodies. Optogenetic stimulation of KNDy neurons drives synchronized GnRH bursts. Lesion the population and the pulse goes quiet. The picture that has emerged in the post-2010 literature is that kisspeptin sits one tier above GnRH in the hierarchy and effectively controls when the system runs.

The Imperial College Human Studies

Most of what we know about kisspeptin in humans comes from one research program. Waljit Dhillo's group at Imperial College London has run a sustained series of clinical studies infusing kisspeptin into healthy volunteers and patients with various reproductive disorders. The first paper appeared in JCEM in 2005 (Dhillo et al.). It established that kisspeptin acutely stimulates LH and FSH release in healthy men, with peak responses at moderate intravenous doses.

The subsequent decade of work expanded the picture. Kisspeptin restored pulsatile gonadotropin secretion in some forms of functional hypothalamic amenorrhea. It reliably distinguished hypothalamic from pituitary causes of hypogonadism — a useful diagnostic role. It produced limbic-system activation on functional MRI when administered in healthy volunteers, suggesting effects beyond simple HPG axis stimulation. And in 2017, Jayasena and colleagues reported kisspeptin enhanced sexual and emotional brain processing in men, with the response correlating with mood scores.

None of this is FDA-approved use. The Imperial work is research-grade pharmacology, peer-reviewed, with protocols approved through standard ethical frameworks for clinical investigation in healthy volunteers and consenting patients.

Half-Life and the KP-10 vs. KP-54 Question

One practical question for research design is which fragment to use. KP-54 has a longer plasma half-life, on the order of tens of minutes. KP-10 is metabolized within a few minutes — fast enough that bolus injections produce sharp, short LH spikes. For studies modeling pulsatile secretion, this is sometimes an advantage: KP-10 produces a clean rise-and-fall, where KP-54 produces a more sustained plateau.

The shorter half-life makes KP-10 the better choice for serial-bolus protocols where the experimenter wants to control timing precisely. For studies measuring sustained gonadotropin output, KP-54 is generally preferred. Dhillo's group has used both in different protocols, and at appropriately matched doses the conclusions about HPG axis function are similar.

What's Still Open

Twenty years after the foundational 2003 papers, kisspeptin biology has unresolved areas. The role of peripheral kisspeptin (the gene is expressed in placenta, adipose tissue, pancreatic islets, and other peripheral sites) is not fully characterized. The question of whether kisspeptin signaling can be safely manipulated long-term in humans for fertility applications is the subject of active research. The interaction between kisspeptin and energy balance — the system is exquisitely sensitive to negative energy balance, which is why functional amenorrhea exists — has mechanistic threads that aren't fully woven together.

What's clearly established is the central architecture. Loss of GPR54 prevents puberty. Kisspeptin is the ligand. KNDy neurons are the pulse generator. Direct kisspeptin administration drives gonadotropin release in nearly every species tested. Twenty years of convergent work, multiple independent labs, a cohesive mechanistic picture. Few peptides have a story as clean.

Sources: Seminara et al., NEJM, 2003; de Roux et al., PNAS, 2003; Funes et al., Biochem Biophys Res Commun, 2003; Kotani et al., J Biol Chem, 2001; Dhillo et al., JCEM, 2005; Jayasena et al., JCI, 2017; Pinilla et al., Physiol Rev, 2012; Plant, Front Neuroendocrinol, 2015.